yh001
mAbexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 21, 2020 (NCT04357756)
Timeline
Indications
Mechanism of action
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05212922 | Phase 2 | Jun 30, 2023 | Eucure (Beijing) Biopharma Co., Ltd |
| NCT05448820 | Phase 1/Phase 2 (Phase 2) | Nov 14, 2022 | Antengene Corporation, Tracon Pharmaceuticals Inc. |
| NCT05176509 | Phase 1 | Apr 5, 2022 | Eucure (Beijing) Biopharma Co., Ltd |
| NCT05169697 | Phase 1 | Feb 21, 2022 | Eucure (Beijing) Biopharma Co., Ltd, Zhejiang University |
| NCT04699929 | Phase 1 | Jan 8, 2021 | Eucure (Beijing) Biopharma Co., Ltd |
| NCT04357756 | Phase 1 | Apr 21, 2020 | Eucure (Beijing) Biopharma Co., Ltd |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eucure (Beijing) Biopharma Co., Ltd | For profit | 5 | 5 | 2 | 2020 |
| Antengene Corporation | For profit | 1 | 0 | 1 | 2022 |
| Tracon Pharmaceuticals Inc. | For profit | 1 | 1 | 1 | 2022 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1